| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US11590081 | TRIS PHARMA INC | Extended release amphetamine tablets |
Sep, 2038
(14 years from now) | |
Dyanavel Xr 5 is owned by Tris Pharma Inc.
Dyanavel Xr 5 contains Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate.
Dyanavel Xr 5 has a total of 4 drug patents out of which 0 drug patents have expired.
Dyanavel Xr 5 was authorised for market use on 04 November, 2021.
Dyanavel Xr 5 is available in tablet, extended release;oral dosage forms.
Dyanavel Xr 5 can be used as method of treating attention deficit hyperactivity disorder.
The generics of Dyanavel Xr 5 are possible to be released after 24 September, 2038.
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 5 family patents
